enGene rose 26.7% on November 12, 2026 after LEGEND showed 12 month bladder cancer complete responses rising to 24% from 13%, against a 3.3% biotech selloff.
Last updated: November 13, 2026
enGene closed at $2.28 on November 12, up 26.7% in the first session after its LEGEND update showed complete responses in BCG unresponsive bladder cancer holding at one year, while the XBI biotech index fell 3.3% on the day.
This briefing covers November 12, 2026: the enGene reaction, the FDA’s weekend action dates, the week’s financings, the Bristol Myers Squibb research reorganization, obesity news ahead of ObesityWeek, and the week’s medtech and diagnostics moves.
How did the market respond to enGene’s LEGEND durability data?
enGene closed at $2.28 on Thursday, up 26.7% from Wednesday’s $1.80 close, in the first reaction session to the LEGEND durability update released Wednesday at 4:03 pm ET. The move landed on the sector’s worst day of the week: the SPDR S&P Biotech ETF fell 3.3% and the S&P 500 slipped 0.4%. All percentages here are our arithmetic from exchange settled closes.
The reaction is the clearest evidence yet for the pattern this publication has tracked all week: data that is counted, mature and tied to a regulator aligned path gets paid, while unquantified ambition gets polite credit at best. enGene entered Wednesday evening priced at $1.80, below its 2026 highs, and the market repriced it 27% higher the moment the durability question had numbers attached, against a tape that was selling everything else.
What did the LEGEND update actually show?
The update covered Cohort 1 of LEGEND, patients with BCG unresponsive non muscle invasive bladder cancer with carcinoma in situ, treated with detalimogene, enGene’s non viral gene therapy delivered into the bladder. With 125 patients enrolled and 120 efficacy evaluable at the October 29 cutoff, the response rate held while durability improved sharply versus the April analysis.
| Measure | April 2026 analysis | November 2026 update |
|---|---|---|
| Complete response at any time | 54% | 56% (CI 47 to 65) |
| Complete response at 12 months (landmark) | 13% | 24% (CI 16 to 33) |
| Duration of response at least 12 months (KM, preliminary) | 25% | 43% (CI 30 to 55) |
| Median duration of complete response | 8.6 months | 10.1 months (CI 7.5 to NE) |
Safety stayed mild: treatment related adverse events in 59% of patients, mostly grade 1 or 2, with 4% grade 3, 2% serious, no grade 4 or 5, and 1% discontinuation. The company reported 97% of patients free of progression to muscle invasive disease and cystectomy free rates of 86% to 96% depending on the measure. enGene said the FDA has aligned on the efficacy evaluable population at a pre BLA meeting, and it plans to initiate a rolling BLA by year end 2026, complete it in the first half of 2027, and reach a potential approval in 2027. The program holds RMAT and Fast Track designations.
enGene did not name competitors in its release. The BCG unresponsive field it would enter includes Adstiladrin, Anktiva and Keytruda; we are not printing cross trial comparisons because the trials differ in populations and measures.
What is the FDA deciding this weekend?
Two action dates fall on Saturday, November 14, which in practice means decisions can land Friday or early next week. The FDA has also repeatedly acted ahead of its dates this year, so neither outcome should be treated as unknowable on a schedule.
| Sponsor | Application | Action date |
|---|---|---|
| Summit Therapeutics | Ivonescimab plus chemotherapy, BLA, EGFR mutant non small cell lung cancer after TKI therapy | November 14, 2026 |
| BioXcel Therapeutics | Igalmi supplemental NDA, use in the at home setting | November 14, 2026 |
Summit shares fell 9.4% Thursday to $15.075 with no company disclosure we could find (scope: searches and the company’s release feed through the end of our build Thursday night). The review file is unusual: the HARMONi trial met progression free survival but its primary overall survival analysis was not statistically significant, and Summit has said the FDA told it a significant survival benefit is needed. In July, Summit disclosed an updated overall survival analysis with a June 2026 cutoff showing the Western subgroup hazard ratio improving to 0.76 from 0.84, still not statistically significant. Fierce Pharma reported at the time that the update likely constitutes a major amendment that could add three months to the review; that is reporting and speculation, not an FDA statement. As of this edition’s close, no approval, rejection or extension had been announced.
How thin is FDA review staffing right now?
The agency deciding those applications is working with meaningfully fewer people. Per FDA hiring data reported by PharmaVoice and BioPharma Dive on Thursday, the drug and biologics review centers CDER and CBER together had 1,343 fewer employees in September 2026 than in September 2024. A BioSpace report put the agency’s June hiring target at roughly 2,200 positions, and STAT has reported that a human resources reorganization is slowing onboarding. At a July House Energy and Commerce health subcommittee hearing, witnesses described reviews as more inconsistent and unpredictable than in the past, with informal feedback harder to get.
Separately, Reuters reported Thursday, citing sources, that the FDA has shelved its Commissioner’s Voucher program for speedy reviews. We could not independently confirm that report by our build close.
For sponsors the practical advice in Thursday’s reporting was concrete: make key data easy to find in submissions, hold early informational meetings, and expect fewer quick phone calls. Every filing in this edition, from enGene’s rolling BLA to Kodiak’s planned Zenkuda submission and Cullinan and Taiho’s completed zipalertinib NDA, goes into that agency.
Who raised money in life sciences this week?
Thursday compressed the capital cycle into one evening. The pattern: data first, raise immediately after.
| Company | Transaction | Detail |
|---|---|---|
| Vir Biotechnology | Common stock offering, priced after Thursday’s close | 15,000,000 shares at $10.00, expected gross proceeds of $150 million, per the pricing release as carried by BiopharmaWatch; about 17% below Thursday’s $12.12 close, our arithmetic. Priced four days after Vir’s Phase 3 hepatitis delta win |
| Windward Bio | IPO priced Thursday evening | 10,294,117 shares at $17.00; $225.0 million expected gross including a concurrent $50.0 million Sanofi private placement; Nasdaq “WWB”; first trade expected Friday, November 13 |
| Guardant Health | Convertible notes | Proposed $500.0 million of converts due 2032, announced Wednesday after the close; shares closed flat Thursday at $154.86 |
| Prime Medicine | Offering closed | Underwriters exercised their option in full; shares fell 9.5% to $3.89 as the deal settled |
| InspireMD | Approval plus raise, same hour | FDA approval of the CGuard Prime carotid stent system for TCAR procedures at 4:01 pm ET, a proposed public offering at 4:15 pm |
| Kodiak Sciences | At the market sales | $69 million net raised after September 30, on $88.7 million of quarter end cash; the quarterly release carries going concern risk language |
Vir is the week’s cleanest illustration of what durable, counted data is now worth: a 44% week 48 response in its Phase 3 ECLIPSE 1 hepatitis delta trial on Monday, an 11.8% rally, and a $150 million raise priced by Thursday night. The pricing came in about 17% below the last close, after the stock had already slipped 7.7% during Thursday’s session, before the offering was announced.
What changed at Bristol Myers Squibb?
Bristol Myers Squibb is combining research and development into a single organization, and its chief research officer is leaving. Per the company’s announcement as reported by BioPharma Dive on Thursday, Robert Plenge, who came to the company with the Celgene acquisition and has led research since 2023, departs after a transition running through March 2027. Cristian Massacesi, currently chief medical officer and head of development, takes the new post of head of R&D on January 1, 2027. The company framed the change as speeding decisions and portfolio management. It lands inside an announced plan to cut another $2 billion in costs by the end of 2027, with pipeline readouts due by the end of the first quarter.
What happened in obesity ahead of ObesityWeek?
Pfizer’s first session after announcing the Blackstone deal was a quiet tax: shares closed down 2.1% at $28.83. Blackstone Life Sciences will fund up to $1.5 billion of development costs for berobenatide, Pfizer’s monthly GLP-1 receptor agonist peptide, through 2028, in exchange for undisclosed milestone payments only.
Eli Lilly broke ground Thursday on its Lehigh Valley, Pennsylvania site for next generation obesity medicines, which the company called its tenth new US site since 2020. The site itself was announced in February 2026 at $3.5 billion, with tirzepatide and retatrutide named as planned products and roughly 850 permanent jobs; those figures are from the February announcement as reported at the time.
ObesityWeek 2026 opens Saturday, November 14 and runs through November 17. Rhythm Pharmaceuticals is expected to present full Phase 3 hypothalamic obesity data for setmelanotide; Novo Nordisk’s STEP Young full data and Corbus’s CANYON-1 late breaker are also on the calendar. Rhythm closed down 2.0% at $109.86 Thursday, Novo Nordisk’s ADRs slipped 1.1%, and Lilly eased 0.7%.
What else crossed the wire on November 12?
Cullinan Therapeutics and Taiho completed the NDA submission for zipalertinib plus chemotherapy in first line EGFR exon 20 insertion non small cell lung cancer, closing out a filing the companies had guided to complete by year end. Regeneron reported that a Phase 2 trial of baloncibart, a first in class NPR1 blocking antibody, reduced orthostatic heart rate and improved symptoms in postural orthostatic tachycardia syndrome; the release headline carried no figures and we are printing none. Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics and its clinical stage Huntington’s disease cell therapy program; terms were not visible in the announcement we read. At the ACAAI allergy meeting, Ionis presented long term DAWNZERA data, Intellia presented lonvo z patient reported data, and DBV Technologies highlighted VITESSE Phase 3 peanut patch data in children ages 4 to 7.
What moved in medtech and diagnostics?
Tandem Diabetes Care is running a correction affecting more than 80,900 Mobi insulin pumps, per the FDA recall database entry dated October 30. The problem is false occlusion alarms traced to drive module friction; Tandem told MedTech Dive it had 230 reports requiring medical intervention or hospitalization as of October 29, with no deaths reported. The FDA has not yet stated a recall class; our explainer on how recall classes work is linked below.
Two diagnostics and digital health deals from earlier in the week deserve the record: Oura agreed Tuesday to buy Counsel Health, an AI primary care company, for $625 million in cash, two months after postponing an IPO that had sought up to $2.2 billion; and Labcorp completed its acquisition of specialty toxicology lab Millennium Health, a deal its quarterly SEC filing values at $245 million cash upfront plus up to $130 million in milestones, up to $375 million in total.
Which stocks carried a story on November 12?
| Ticker | Close | Move | The story |
|---|---|---|---|
| ENGN | $2.28 | +26.7% | First reaction to LEGEND durability data, against the sector tape |
| SMMT | $15.075 | −9.4% | Into Saturday’s ivonescimab action date; no company disclosure found |
| MANE | $135.29 | −13.6% | No cause found; rose 5.5% Wednesday, also without disclosure |
| PRME | $3.89 | −9.5% | Offering closed with the underwriters’ option exercised in full |
| VIR | $12.12 | −7.7% | Session slide before the after market offering launch; pricing reaction comes Friday |
| PFE | $28.83 | −2.1% | First reaction to the Blackstone berobenatide funding deal |
Context: XBI 151.20, down 3.3%; SPY 757.12, down 0.4%. All closes are exchange settled; all percentages are our arithmetic.
Frequently asked questions
Why did enGene stock jump 27 percent on November 12, 2026?
It was the first trading session after enGene released updated LEGEND trial data showing complete responses in BCG unresponsive bladder cancer lasting longer: the 12 month landmark complete response rate rose to 24% from 13% in the April analysis.
What is detalimogene and how is it given?
Detalimogene is enGene’s non viral gene therapy for bladder cancer, delivered directly into the bladder. It is designed for durable local gene expression without viral vector manufacturing constraints.
What complete response rates did LEGEND show?
A 56% complete response rate at any time among 120 efficacy evaluable patients, a 24% landmark complete response rate at 12 months, and a preliminary Kaplan Meier estimate that 43% of responses last at least 12 months.
When will enGene file for approval?
enGene plans to initiate a rolling BLA by the end of 2026 and complete it in the first half of 2027, with potential approval in 2027. The program holds RMAT and Fast Track designations.
How does detalimogene compare with Adstiladrin or Anktiva?
They target the same BCG unresponsive bladder cancer setting, but the trials differ in populations and endpoints, so response rates are not directly comparable. enGene itself named no comparators.
When is the FDA decision on ivonescimab?
Summit Therapeutics’ action date is Saturday, November 14, 2026, for ivonescimab plus chemotherapy in EGFR mutant non small cell lung cancer after TKI therapy. Decisions can arrive before or after the date.
Could the ivonescimab decision be delayed?
Fierce Pharma reported in July that Summit’s updated survival analysis likely constitutes a major amendment, which can extend a review by three months. The FDA has not confirmed any extension publicly.
What is BioXcel’s November 14 decision about?
A supplemental NDA to allow Igalmi, its sublingual dexmedetomidine film, to be used in the at home setting rather than only under supervision.
How many staff has the FDA lost in its review centers?
CDER and CBER together had 1,343 fewer employees in September 2026 than in September 2024, per FDA hiring data reported by PharmaVoice and BioPharma Dive.
What did Vir Biotechnology price its offering at?
Per the pricing release as carried by BiopharmaWatch, 15 million shares at $10.00 for expected gross proceeds of $150 million, about 17% below Thursday’s close.
What is Windward Bio and when does it start trading?
A Basel based clinical stage company developing ultra long acting antibodies for respiratory and dermatologic diseases. Its $225 million IPO priced at $17.00 Thursday, with trading on Nasdaq as WWB expected to begin Friday, November 13. Sanofi bought $50 million in a concurrent private placement.
Who is replacing Robert Plenge at Bristol Myers Squibb?
Cristian Massacesi, the current chief medical officer and head of development, becomes head of a newly combined R&D organization on January 1, 2027. Plenge stays through March 2027 for the transition.
What is Eli Lilly building in the Lehigh Valley?
A $3.5 billion injectable medicines site in Pennsylvania announced in February 2026, intended for next generation obesity medicines including tirzepatide and retatrutide. Lilly broke ground on November 12, 2026.
What does Kodiak’s going concern language mean?
Kodiak’s quarterly release lists substantial doubt about continuing as a going concern among its risks, with $88.7 million of cash at September 30 plus $69 million raised since. It still plans to submit its multi indication Zenkuda BLA by year end.
When does ObesityWeek 2026 run?
Saturday, November 14 through Tuesday, November 17, 2026, with Rhythm’s full Phase 3 hypothalamic obesity data among the expected presentations.
Sources
Company releases and filings (primary): enGene LEGEND Cohort 1 update, Business Wire, November 11, 2026. Windward Bio IPO pricing release, GlobeNewswire, November 12, 2026. Kodiak Sciences third quarter 2026 release, ir.kodiak.com, November 12, 2026. Summit Therapeutics third quarter 2026 release, November 4, 2026. Pfizer and Blackstone Life Sciences funding agreement release, Business Wire, November 11, 2026. Vir Biotechnology ECLIPSE 1 topline release, November 8, 2026. Cullinan Therapeutics and Taiho NDA completion release, November 12, 2026. Regeneron baloncibart Phase 2 release, November 12, 2026. Labcorp quarterly SEC filing (Millennium Health terms).
Attributed reporting: Vir offering pricing figures per the pricing release as carried by BiopharmaWatch, November 12, 2026 (primary release not independently retrieved by our build close). BioPharma Dive, November 12, 2026 (Bristol Myers Squibb reorganization; FDA staffing, first published on PharmaVoice). Reuters, November 12, 2026 (Commissioner’s Voucher program report, citing sources). MedTech Dive, November 9 to 11, 2026 (Tandem Mobi recall with FDA recall database entry of October 30; Oura and Counsel Health; Labcorp and Millennium Health). Fierce Pharma, July 2026 (Summit survival data update and major amendment analysis). Eli Lilly February 2, 2026 site announcement as reported by BioSpace (Lehigh Valley investment figures).
Market data: exchange settled closing prices, November 12, 2026; percentage moves are our arithmetic.
